Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial year, surpassing its EUR 6 billion target and reinforcing confidence in its 2030 strategic trajectory. Growth was led by strong oncology performance, particularly in the United States, while core products and expanded geographic reach supported broader momentum.
Contents
Financial Performance Summary
| Metric | 2024/25 Result | YOY Growth | Strategic Impact |
|---|---|---|---|
| Total Revenue | EUR 6.9 B (USD 7.52 B) | +16.2% | Exceeded EUR 6 B target |
| Oncology Revenue | EUR 2.21 B (USD 2.41 B) | +54.6% | 32.2% of Group revenue |
| Cardiometabolism/Venous | EUR 2.97 B (USD 3.24 B) | +1.8% | Stable core portfolio |
| Brand‑Name Business | — | +18.1% | Key growth driver |
| Generics | — | +10.3% | Solid contribution |
Key Product & Segment Drivers
| Segment | Revenue | Growth | Key Drivers |
|---|---|---|---|
| Oncology | EUR 2.21 B | +54.6% | Voranigo (vorasidenib) US launch uptake |
| Cardiometabolism/Venous | EUR 2.97 B | +1.8% | Daflon and established brands |
| Geographic Strategy | — | — | US becomes largest unit, EU remains core |
Geographic Performance Highlights
| Region | Revenue | YOY Growth | % of Group Revenue |
|---|---|---|---|
| United States | EUR 1.496 B (USD 1.63 B) | +70.3% | 21.8% (largest single unit) |
| European Union | — | +9.2% | 40.5% (core market) |
| International Markets | — | Growing | Reflects diversification strategy |
Strategic Implications & Outlook
- Oncology Leadership: Voranigo’s strong US uptake validates Servier’s pivot toward high‑value oncology assets, positioning the company as a credible competitor in brain cancer therapy
- US Market Transformation: 70% revenue surge in the US reflects successful commercial infrastructure investment and regulatory execution
- Portfolio Balance: While oncology drives headline growth, cardiometabolism/vascular franchise provides stable cash flow to fund R&D expansion
- Geographic Diversification: International market growth reduces reliance on European reimbursement pressures
- 2030 Trajectory: Management expects oncology growth—especially in the US—to remain a key driver in the coming financial year, alongside stable core portfolio performance
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Servier’s revenue projections, market growth, and strategic execution toward 2030 goals. Actual results may differ due to competitive dynamics, regulatory changes, and market access challenges.-Fineline Info & Tech
